Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET H SHARE REPURCHASE

This announcement is made by Pharmaron Beijing Co., Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Reference is made to the circular of the Company dated May 14, 2024 (the "**Circular**") and the announcement of the Company dated June 6, 2024 (the "**Announcement**") in relation to the grant of general mandate to repurchase H Shares of the Company. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board would like to announce that it intends to exercise its powers under the Repurchase Mandate given to the Board pursuant to the special resolution of the Shareholders passed at the 2023 AGM and the Class Meetings held on June 6, 2024, to repurchase H Shares of the Company (the "**H Share Repurchase**").

On 8 December, 2024, the Board determined to utilize the Repurchase Mandate and, subject to market conditions, repurchase H Shares in the open market from time to time. Based on the expectations for the Company's future development prospects, the Board believes that the H Share Repurchase under the current market conditions will safeguard the Company's value and protect Shareholders' rights and interests without affecting the Company's duty to maintain a sufficient public float.

The implementation period of the H Share Repurchase (the "**Repurchase Period**") shall commence on the date when the Board approves the H Share Repurchase and shall end on the earliest of the following dates:

i. the expiration of 12 months after the conclusion of the 2023 AGM (which is June 5, 2025);

ii. the conclusion of the 2024 annual general meeting of the Company; or

iii. the revocation or variation of the authority granted under the Repurchase Mandate by passing of a special resolution at any general meeting of the Company.

The actual repurchase price will be determined with reference to the actual market conditions and in compliance with the listing rules and all applicable laws and regulations of the places where the Company's shares are listed.

Pursuant to the Repurchase Mandate, the Company is authorized to repurchase up to 15,076,856 H Shares, representing 5% of the total number of H Shares in issue as at the date of passing the special resolution at the 2023 AGM and the Class Meetings of the Company. The repurchased H Shares will be held as treasury H Shares, and might be resold, paid to share incentive schemes or otherwise as permitted by the listing rules of the places where the Company's shares are listed, or cancelled. The Company will perform the relevant registration and filing procedures required by all applicable laws and regulations with which the Company is subject to.

The Company intends to fund the H Share Repurchase from its own financial resources, with a maximum amount of RMB50 million intended to be utilize. The Board has authorized the senior management of the Company, in light of the share price, financial and operational conditions during the Repurchase Period, to adjust the maximum amount where necessary. The Board believes that the current financial resources of the Company will enable it to implement the H Share Repurchase while maintaining a sound financial position.

As at the time of this announcement, the Company has not repurchased any H Shares. Shareholders and potential investors should note that any repurchase will be subject to market conditions and compliance with any regulatory procedures (including but not limited to foreign exchange approvals) and/or approvals that may be required for the repurchase, and at the sole discretion of the Board. The Company makes no assurance as to whether any repurchase of H shares will be made, or the timing, quantity or price of any repurchase of H shares. Accordingly, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Pharmaron Beijing Co., Ltd.
Dr. Lou Boliang
Chairman

Beijing, the PRC
9 December 2024

As at the date of this announcement, the Board comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.